Загрузка...
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...
Сохранить в:
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science (PLoS)
2018-01-01
|
| Серии: | PLoS ONE |
| Online-ссылка: | http://europepmc.org/articles/PMC5976165?pdf=render |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|